Scribe Therapeutics Reports Q2 2026 Financial Results

What Happened

• Scribe Therapeutics, Inc. announced its financial results and provided a business update for the quarter ended June 30, 2026. The company filed a Current Report on Form 8-K on September 2, 2026 and furnished the related earnings press release as Exhibit 99.1, which is incorporated by reference into the filing. The 8-K was signed by CEO Benjamin L. Oakes, Ph.D.

Key Details

• Filing date: September 2, 2026.
• Reporting period: quarter ended June 30, 2026.
• Press release: Issued September 2, 2026 and furnished as Exhibit 99.1 to the 8-K (contains the detailed earnings/financial results and business update).
• Signature: Form 8-K signed by Benjamin L. Oakes, Ph.D., Chief Executive Officer.

Why It Matters

• The 8-K signals that Scribe has released its latest quarterly earnings and operational update; investors should review the furnished press release (Exhibit 99.1) for revenue, net income/loss, cash position, and any guidance or material business developments.
• This is a routine but material disclosure under Item 2.02 (results of operations and financial condition); the specifics that will affect valuation and near-term trading — such as revenue, R&D expenses, or cash runway — are in the press release itself.
• Retail investors tracking Scribe should read the Exhibit 99.1 press release and any subsequent SEC filings for the full financial details and management commentary.